نتایج جستجو برای: dmard therapy

تعداد نتایج: 654381  

Journal: :Annals of the rheumatic diseases 2012
L Gossec J S Smolen C Gaujoux-Viala Z Ash H Marzo-Ortega D van der Heijde O FitzGerald D Aletaha P Balint D Boumpas J Braun F C Breedveld G Burmester J D Cañete M de Wit H Dagfinrud K de Vlam M Dougados P Helliwell A Kavanaugh T K Kvien R Landewé T Luger M Maccarone D McGonagle N McHugh I B McInnes C Ritchlin J Sieper P P Tak G Valesini J Vencovsky K L Winthrop A Zink P Emery

BACKGROUND Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). MET...

Journal: :Inflammopharmacology 2015

2014
OU Loskutova (Konopelko) ES Zholobova MN Nikolaeva LA Galstian

Methods The study enrolled 54 pediatric patients with polyarticular JIA, 32 of them received etanercept and 22 received abatacept. The demographic parameters were well matched across treatment groups. The mean age of children was 10.8 ± 3.7, the age at the disease onset was 5.4 ± 3.4, most of the patients were female. Prior to biological DMARD administration, all the subjects received multiple ...

2016
Lily Dubey Suparna Chatterjee Alakendu Ghosh

OBJECTIVES Methotrexate (MTX) is the most commonly used cost-effective disease-modifying antirheumatoid drug (DMARD). Its main dose-limiting adverse effects are hepatic and hematopoietic. This cross-sectional, observational study evaluated the prevalence of hepatic and hematological adverse effects with long-term low-dose MTX therapy. MATERIALS AND METHODS Rheumatoid arthritis (RA) patients t...

Journal: :Rheumatology 2003
P S Helliwell G Ibrahim

BACKGROUND AND OBJECTIVE The UK has a growing South Asian population. In the South Asian population of Bradford people appear to be less tolerant of disease-modifying anti-rheumatic drugs (DMARDs). One reason for this may be poor communication during patient education, which is generally designed for white North European people. Our objective was to obtain information on DMARDs that were used, ...

Journal: :Annals of the rheumatic diseases 2005
A Zink J Listing S Kary P Ramlau M Stoyanova-Scholz K Babinsky U von Hinueber E Gromnica-Ihle S Wassenberg C Antoni P Herzer J Kekow M Schneider R Rau

OBJECTIVE To compare drug continuation rates in patients with rheumatoid arthritis who start on a biological agent and in a control group of patients with a change in disease modifying antirheumatic drug (DMARD) treatment after previous DMARD failure. METHODS Patients with rheumatoid arthritis enrolled in the German biologics register between May 2001 and September 2003 were included in the s...

Journal: :Clinical and experimental rheumatology 1999
W Bensen W Bensen

Combination disease-modifying antirheumatic drug therapy with methotrexate and hydroxychloroquine has changed the course of rheumatoid arthritis. Better management requires "front of the line" care, effective drug combinations, and a goal of "Personal Best." The Pincus phenomenon--the discrepancy between subjective satisfaction and objective progression--may be minimized in clinical practice by...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید